The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings
· cnbc.com
As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.
"While Novo raised guidance (as expected), the pipeline and path to sustainable growth remain less clear," BMO Capital Markets analyst Evan Seigerman said in a ...